Core Viewpoint - The article discusses the recent advancements in the development of UBT251, a three-target receptor agonist for weight loss, co-developed by Federal Pharmaceuticals and Novo Nordisk, highlighting its significant weight reduction efficacy and safety profile in clinical trials [5][7]. Group 1: Clinical Trial Results - The Phase II clinical trial of UBT251 in China showed that after 24 weeks, the treatment group experienced an average weight reduction of 19.7% (-17.5 kg), compared to a 2.0% (-1.6 kg) reduction in the placebo group [5]. - In addition to weight loss, UBT251 demonstrated statistically significant improvements in waist circumference, blood sugar, blood pressure, and blood lipids compared to the placebo group [5]. - The safety profile of UBT251 was reported to be good, with the most common adverse events being gastrointestinal reactions, mostly mild to moderate, which decreased over time [5]. Group 2: Industry Competition and Collaboration - UBT251 is considered an important asset in Novo Nordisk's new generation weight loss pipeline, representing an upgrade in the mechanism of weight loss drugs by targeting GLP-1, GIP, and GCG pathways simultaneously [7]. - The collaboration structure between Federal Pharmaceuticals and Novo Nordisk reflects a new division of labor in innovative drug development, allowing local companies to retain long-term rights in core regions while leveraging the global capabilities of multinational firms [7]. Group 3: Future Development Plans - Novo Nordisk has initiated a global Phase Ib/IIa study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of UBT251 in approximately 330 overweight or obese patients, with major data expected to be released in 2027 [8]. - Federal Pharmaceuticals plans to present detailed data from the Phase II study at an upcoming medical conference and will advance to Phase III clinical trials for overweight or obese patients in China based on the results [8].